Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  therapeutic autologous lymphocytes
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 79 for your search:
Start Over
Two Different Methods of Collecting Stem Cells For an Autologous Stem Cell Transplant in Treating Patients With Diffuse Large Cell Lymphoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: MC0681, P30CA015083, 07-000789, MAYO-MC0681, NCT00566228
Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: IcmLCBT_301, NCT00807027
GVAX in Advanced Prostate Cancer Patients Made Lymphopenic
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: PPMC-EACRI-IRB-02-119, DOD Grant #DAMD17-03-1-0097, NCT00122005
Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 to 75
Sponsor: Other
Protocol IDs: rM28-001, NCT00204594
Autologous Cytokine-induced Killer Cell Adoptive Immunotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 12 to 75
Sponsor: Other
Protocol IDs: CIK#1/2006, NCT00394381
Activated White Blood Cells in Treating Patients Undergoing an Autologous Stem Cell Transplant for Newly Diagnosed Stage II or Stage III Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: J0770 JHU, P30CA006973, JHOC-J0770, J0770, NCT00566098
High-dose Chemotherapy With Transplantation of Gene-modified Haematopoietic Stem Cells for HIV-positive Patients With Malignant Diseases Indicating an HSCT
Phase: Phase II, Phase I
Type: Treatment
Status: Temporarily closed
Age: 18 to 65
Sponsor: Other
Protocol IDs: ARL-GT 2005, NCT00858793
Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma
Phase: Phase II, Phase I
Type: Treatment
Status: Temporarily closed
Age: 19 months to 35 years
Sponsor: NCI
Protocol IDs: 070206, 07-C-0206, NCT00923351
Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 to 80
Sponsor: Other
Protocol IDs: CDR0000256870, MSGCC-0065, UPCC-6401, NCI-V02-1709, NCT00046852
Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 to 75
Sponsor: Other
Protocol IDs: 2179.00, NCI-2010-01281, FHCRC-2179.00, 6558, NCT00553306
T Regulatory Lymphocytes (Treg) Depletion for Cancer Treatment Efficacy and Safety Study
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 to 65
Sponsor: Other
Protocol IDs: P080601, NCT00986518
Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TVI-AST-002, NCT01081223
Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 to 70
Sponsor: NCI, Other
Protocol IDs: 09174, NCI-2011-00344, P50 CA107399, NCT01318317
Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CDR0000064192, NCI-95-C-0105A, NCI-T94-0096N, T94-0096, NCT00019084
A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas
Phase: Phase II
Type: Treatment
Status: Completed
Age: 30 and under
Sponsor: NCI
Protocol IDs: 970050, 97-C-0050, NCI-97-C-0050K, NCI-T96-0037, T96-0037, NCT00019279, NCT00001564
Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000067241, P30CA022453, WSU-C-1403-ME, NCI-G99-1565, NCT00004022
Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000067243, P30CA022453, WSU-C-1403-BT, NCI-G99-1567, NCT00004024
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: 990158, 99-C-0158, NCI-99-C-0158, NCI-T99-0078, T99-0078, NCT00019942, NCT00001832
Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 65 and under
Sponsor: NCI, Other
Protocol IDs: CDR0000068559, P30CA022453, WSU-D-1654, WSU-07-92-98-P04-FB, NCI-G01-1937, NCT00014573
Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: CDR0000354491, NCI-04-C-0104, NCI-6233, 6233, NCT00079144
Cellular Adoptive Immunotherapy in Treating Patients With Glioblastoma Multiforme
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: Other
Protocol IDs: CDR0000471241, HOAG-CBRG-98-09, NCT00331526
Start Over